Smoldering multiple myeloma (SMM) is a precancerous condition, not active cancer. It sits in a gray zone between a benign blood condition called MGUS and full-blown multiple myeloma. Abnormal plasma cells are accumulating in the bone marrow and producing detectable levels of abnormal protein in the blood, but they haven’t yet caused any damage to the body. That distinction, the absence of organ damage, is what separates smoldering myeloma from cancer that needs treatment.
What Makes It Different From Active Myeloma
The dividing line between smoldering myeloma and active multiple myeloma comes down to four types of organ damage, collectively known as CRAB: elevated calcium in the blood, kidney dysfunction, anemia, and bone lesions. In active myeloma, the abnormal plasma cells have grown aggressive enough to cause at least one of these problems. In smoldering myeloma, none of them are present. The plasma cells are there, the abnormal protein is measurable, but the body is functioning normally.
To receive a smoldering myeloma diagnosis, you need either a certain level of abnormal protein in the blood (at least 3 g/dL) or abnormal plasma cells making up 10 to 60 percent of bone marrow cells, and critically, no signs of organ damage or amyloidosis. If the plasma cell percentage reaches 60% or above, or if imaging reveals bone involvement, the diagnosis gets reclassified as active myeloma regardless of symptoms. The International Myeloma Working Group made that reclassification in 2014, recognizing that extremely high levels of plasma cells are dangerous enough to warrant immediate treatment even without obvious symptoms.
Where SMM Falls on the Spectrum
Think of it as a three-stage progression. MGUS (monoclonal gammopathy of undetermined significance) is the earliest stage, with lower levels of abnormal protein and fewer plasma cells in the bone marrow. Smoldering myeloma is the middle stage, with higher protein levels and more plasma cells but still no damage. Active multiple myeloma is the final stage, where the disease is causing harm and treatment becomes necessary.
The key difference between MGUS and SMM is scale. In MGUS, the abnormal protein is below 3 g/dL and plasma cells make up less than 10% of bone marrow. In SMM, one or both of those numbers are higher. Neither condition causes symptoms you’d notice in daily life. Both are typically discovered incidentally during routine blood work.
How Likely It Is to Become Cancer
Not everyone with smoldering myeloma will progress to active cancer, but the risk is real and highest in the early years after diagnosis. A landmark study found the overall risk of progression was about 10% per year for the first five years, dropping to roughly 3% per year for the next five years, and about 1% per year after that. More recent data from the American Society of Hematology suggests the actual annual progression rate during the first five years may be somewhat lower, closer to 6.8%, followed by 2.9% per year for the next five years.
The risk varies enormously depending on individual factors. Doctors now use a scoring system called the 2/20/20 model to estimate your personal risk. It looks at three things: whether your abnormal protein level exceeds 2 g/dL, whether plasma cells make up more than 20% of your bone marrow, and whether your free light chain ratio (a measure of how imbalanced your antibody production has become) exceeds 20. If none of those thresholds are crossed, you’re low risk, with roughly a 6% chance of progressing within two years. One risk factor puts you at intermediate risk (about 18% chance within two years). Two or more puts you at high risk, with a 44% chance of progression within two years.
What Monitoring Looks Like
The standard approach for most people with smoldering myeloma is close observation rather than treatment. Guidelines recommend check-ups every three to six months, which include blood tests measuring kidney function, calcium, blood cell counts, and protein levels. Urine tests track whether abnormal protein is spilling into the kidneys. Bone imaging is typically done once a year to watch for early signs of skeletal damage. Bone marrow biopsies and advanced imaging scans are performed when something changes or when your doctor needs a closer look.
This monitoring isn’t passive. It’s designed to catch the transition to active myeloma as early as possible, so treatment can begin before significant organ damage occurs. The risk of transformation is lifelong, which means monitoring continues indefinitely even if your numbers stay stable for years.
When Treatment Starts Early
For people with high-risk smoldering myeloma, the conversation around treatment is shifting. Traditionally, doctors waited until CRAB features appeared before starting therapy. But recent evidence is changing that calculus.
A systematic review and meta-analysis of randomized controlled trials found that people with smoldering myeloma who received early treatment had a 60% lower risk of disease progression or death compared to those who were simply observed. The benefit was even more dramatic for high-risk patients specifically, who saw a 72% reduction in risk of progression. When looking at overall survival (the most important measure), treated patients had a 45% lower risk of death compared to those on observation alone.
These results are pushing guidelines to evolve. Current recommendations allow doctors to start therapy for high-risk smoldering myeloma patients without waiting for organ damage to appear. Clinical trials are also actively enrolling SMM patients to refine which treatments work best and who benefits most from early intervention.
The Practical Bottom Line
Smoldering myeloma is not cancer in the way most people understand that word. It won’t make you feel sick, it doesn’t require chemotherapy in most cases, and many people live with it for years or even decades without it ever progressing. But it’s also not nothing. It represents a measurable, monitored risk that your body could develop active multiple myeloma over time. Your individual risk profile, particularly where you fall on the 2/20/20 scale, determines how aggressive your monitoring should be and whether early treatment might be worth considering.